Cost-Effectiveness of Care Coordination for Children With Chronic Noncomplex Medical Conditions: Results From a

Hannah E Carter1, John Waugh2, Anne B Chang3

  • 1Australian Centre for Health Services Innovation and Centre for Healthcare Transformation, School of Public Health and Social Work, Queensland University of Technology, Kelvin Grove, QLD, Australia.

Insights

Care coordination for children with chronic conditions is cost-effective, offering improved health outcomes and minimal additional costs within the Australian healthcare system. This approach enhances family-centered care across various sectors.

Area of Science:

  • Health Economics
  • Pediatric Healthcare
  • Chronic Disease Management

Background:

  • Children with chronic noncomplex medical conditions often require coordinated healthcare services.
  • Standard care may not adequately address the multifaceted needs of these children and their families.
  • Evaluating the economic impact of enhanced support is crucial for healthcare policy.

Purpose of the Study:

  • To determine the cost-effectiveness of a care coordination model compared to standard care for pediatric patients with chronic noncomplex conditions.
  • To analyze health system costs and quality-adjusted life-years (QALYs) over a 12-month period.
  • To assess the economic value of care coordination from the Australian health system's perspective.

Main Methods:

  • A multicenter randomized controlled trial involving 81 children aged 2-15 years with newly diagnosed chronic noncomplex conditions.
  • Intervention group received care coordination via an Allied Health Liaison Officer, facilitating access across healthcare, education, and community sectors.
  • Cost-effectiveness analysis included health system costs, QALYs, and caregiver productivity, with sensitivity analyses to address uncertainty.

Main Results:

  • The care coordination group incurred minimal additional health system costs (average $17) and gained 0.031 QALYs over 12 months.
  • The incremental cost-effectiveness ratio was $548 per QALY.
  • There was a 73% probability that care coordination was cost-effective, rising to 78% when caregiver productivity was included, assuming a willingness to pay of $50,000 per QALY.

Conclusions:

  • Care coordination represents a likely cost-effective intervention for managing children with chronic noncomplex medical conditions in Australia.
  • The findings support the integration of dedicated liaison roles to improve healthcare access and outcomes for this population.
  • This model offers a favorable economic return for the Australian healthcare setting.
Abstract

Related Concept Videos

Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
622
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.3K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
168
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
7.1K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
76
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
234